Introduction {#s1}
============

Acute kidney injury (AKI) is defined by rapid kidney function decline, over several hours to days, with contradistinction to chronic kidney disease.[@b1] It is a common complication of critically ill cirrhotic patients (CICPs) and is a common reason for which CICPs are admitted to the intensive care unit (ICU).[@b2],[@b3] In patients with stable cirrhosis, studies have found that hypoalbuminemic alkalosis, dilutional acidosis and hyperchloremic acidosis work together to achieve a compensatory effect, in which alkalizing and acidifying acid-base disturbances can achieve an equilibrium that eventually results in a stable metabolic acid-base state.[@b4],[@b5]

No data to date is available for disorders of acid-base homeostasis in CICPs with AKI. Acid-base data have been interpreted by traditional methods that contain the parameters of standard base excess, bicarbonate (HCO^3−^), anion gap (AG), and pH.[@b6] The standard base excess, a calculated data value, assumes normal plasma protein and electrolyte content.[@b7] The observed AG also ignores the role of major non-bicarbonate buffers in blood plasma, such as plasma proteins and inorganic phosphate.[@b8] However, CICPs with AKI always present with electrolyte and protein abnormalities. Thus, the physicochemical approach performed by Stewart for acid-base disturbances has been applied in clinical practice, particularly for critically ill patients.[@b9]

In addition, the Gilfix methodology, a simple bedside approach based on the fundamental principles of the Stewart method, can be used to analyze base excess compounds.[@b10] The Gilfix method proposed that non-respiratory acid--base disturbance may be attributed to the following: changes in strong ions due to free water deficit or excess, determined by changes in sodium concentration, and changes in chloride concentration; changes in protein charges (mainly albumin); and presence of unmeasured organic anions.[@b11],[@b12] Although the Stewart model theory and the Gilfix method have been used previously to better understand acid-base homeostasis in critically ill patients,[@b13],[@b14] there has been no report to evaluate their ability to predict mortality in CICPs with AKI.

It is generally understood that one cannot separate acid-base effects of CICPs from AKI; therefore, comprehending the contribution of AKI to acid-base disorders becomes essential to opening avenues for novel screening methods that may provide better physiological diagnosis and prognosis. This study aims to identify and describe the composition of metabolic acidosis in CICPs with AKI and their relationship with hospital mortality.

Methods {#s2}
=======

The database and patients {#s2-1}
-------------------------

The data for this study was extracted from the Medical Information Mart for Intensive Care version 3.0 (MIMIC-III v3.0), a comprehensive and free database. With permission, we were allowed access to medical records of patients treated in the ICU from 2001 to 2012 at Beth Israel Deaconess Medical Center (our certification number: 1605699). The data used were non-patient identifiable and anonymous; detailed descriptions have been reported in our previous studies.[@b15],[@b16]

In this study, we extracted a total of 1460 consecutive CICPs from the MIMIC-III v3.0 database. Ultimately, 380 in-hospital patients in the ICU were deemed eligible for study inclusion. Criteria for inclusion were as follows: diagnosis of liver cirrhosis and older than 18 years; diagnosis of AKI followed-up for at least 30 days; no history of liver transplantation; no history of end-stage renal disease; no regular renal replacement therapy; and admitted to the hospital for more than 24 h.

CICPs, defined as patients with critically ill cirrhosis, were enrolled in our study when admitted to the ICU. The criteria of liver cirrhosis and AKI in the present study were described in our previous studies.[@b15]--[@b17] For patients without a serum creatinine (SCr) value prior to hospitalization, we used the first SCr value measured during hospitalization as the baseline SCr, in compliance with recommendations of the International Club of Ascites.[@b18] In addition, the models for end-stage liver disease (commonly known as MELD), chronic liver failure-sequential organ failure assessment (CLIF-SOFA), simplified acute physiology score (commonly known as SAPS II), SOFA score, and kidney disease improving global outcomes (commonly known as KDIGO) criteria were calculated to evaluate the severity of CICPs with AKI.

Sampling and blood analysis {#s2-2}
---------------------------

Our investigators extracted detailed patient records, typically containing demographic and laboratory parameters as well as survival time. The clinical parameters were derived from the hospital's online information systems. The laboratory parameters from routine tests on admission were extracted into a relational database. Patient arterial blood was collected on admission. SCr was evaluated upon admission and at least once every 24-h interval. The urine output was calculated for the first 24 h after ICU admission, recorded at least 6 h intervals. Social Security Death Records from the USA government provided the time of death. Patient data was obtained using Oracle Structured Query Language Developer version 3.0 (Oracle Corporation, Redwood Shores, CA, USA).

Acid-base analysis {#s2-3}
------------------

Arterial HCO^3−^, standard bicarbonate (HCO^3−^~st~), base excess (BE) and standard base excess measurements were carried out according to Henderson-Hasselbach and Siggaard-Andersen equations respectively.[@b19] In the present study, pH \<7.35 was defined as acidemia, pH \>7.45 as alkalemia, HCO^3−^ \<22 mmol/L as net metabolic acidosis, HCO^3−^ \>26 mmol/L as alkalosis, and lactate \>2.2 mmol/L as lactic acidosis.

Acid-base analysis was performed using Stewart equations and the Gilfix methodology. In the Gilfix methodology, lactate levels, unmeasured anions, hypoalbuminemia, chloride levels, and changes of plasma can influence BE. Based on this concept, we calculated the BE compounds in comparison with the effects of electrolytes, albumin, lactate and unmeasured anions.[@b10],[@b14] The means of reference values were used as normal values. The effective strong ion difference was necessary for the role of weak acids (CO~2~, albumin, and phosphate) in the balance of electrical charges in plasma.

Calculated acid-base variables {#s2-4}
------------------------------

1.  BE caused by free water effect (BE~Na~) = 0.3 × (Na--Na~normal~); Na~normal~ = 140 mmol/L, BE~Na~ \<−5 mmol/L was defined as dilutional acidosis, and BE~Na~ \> +5 mmol/L as concentrational alkalosis, respectively.

2.  Cl~Na-corrected~ = Cl × Na~normal~/Na; BE~Cl~ = Cl~normal~--Cl~Na-corrected~ BE~Cl~ \<−5 mmol/L was defined as hyperchloremic acidosis, and BE~Cl~ \> +5 mmol/L as hypochloremic alkalosis.

3.  BE~Lac~ = lactate~normal~--lactate~measured~; Lactate~normal~ = 0.8 mmol/L

4.  BE~Alb~ = (0.148 × pH-0.818) × (albumin~normal~ --albumin~measured~) BE~Alb~ \> +5 mmol/L was defined as hypoalbuminemic alkalosis.

5.  BE~UMA~ = BE -- (BE~Na~ + BE~Cl~ + BE~Alb~ + BE~Lac~) BE~UMA~ \<−5 mmol/L was defined as metabolic acidosis due to unmeasured anions.

6.  BE = BE~Na~ + BE~Cl~ + BE~Alb~ + BE~Lac~ + BE~UMA~

7.  AG = \[Na^+^\] + \[K^+^\] − \[Cl^−^\] − \[HCO^3−^\]

8.  AG~corrected~ = AG + 0.25 × (45 − observed albumin in g/L)

9.  Strong ion difference-apparent (SIDa) = \[Na^+^\] + \[K^+^\] + \[Ca^2+^\] + \[Mg^2+^\] − \[Cl^−^\] − lactate

10. Strong ion difference-effective (SIDe) = partial pressure of carbon dioxide × 2.46 × 10 ^pH-8^ + albumin × (0.123 × pH − 0.631) + 2 × phosphate × (0.309 × pH − 0.469)

11. Strong ion gap (SIG) = SIDa − SIDe

Statistical analysis {#s2-5}
--------------------

In the present study, continuous variables were presented as means (standard derivations) if data were normally distributed, and categorical variables were expressed by frequencies (percentages). For comparisons, the Student's *t*-test and the Mann-Whitney test was used for continuous baseline characteristics of each group for continuous variables with or without normal distribution, respectively. The χ^2^-test was performed for categorical variables. Data were compared by χ^2^-test for categorical variables and a one-way analysis of variance for continuous variables. Multivariate analysis was carried by Cox regression to test the association between acid-base state and ICU 30-day mortality.

The diagnostic performance was examined by area under the receiver operating characteristic curve (AUROC). The cut-off point was calculated according to the max value of Youden index, and the specificity, positive likelihood ratio, negative likelihood ratio, corresponding sensitivity, positive predictive value, and negative predictive value for relevant cut-offs were also calculated. All patients were enrolled for a comparison of diagnostic performance of the CLIF-SOFA, lactate, BE~UMA~, CLIF-SOFA + LAC, CLIF-SOFA + BE~UMA~ and CLIF-SOFA + LAC + BE~UMA~ for predicting 30-day mortality rate. Statistical analyses were performed using SPSS version 22.0 software (IBM Corp., Armonk, NY, USA) and MedCalc version 12.7 (MedCalc Software, Ostend, Belgium). A two-tailed *p* \< 0.05 was considered to be statistically significant.

Results {#s3}
=======

Baseline characteristics of CICPs with AKI {#s3-1}
------------------------------------------

In this study, we found that the mean age of 380 CICPs with AKI was 57 years and 71.05% (270 of 380) were male. Both survivors (*n* = 254, 66.84%) and non-survivors (*n* = 126, 33.16%) had similar respective age (56.95 ± 10.58 vs. 57.74 ± 11.59) as well as sex (70.47% vs. 72.22% males). The cause, complication and comorbidity of cirrhosis, clinical scores, as well as demographic, clinical and laboratory parameters were collected for both survivors and non-survivors. The patients in the non-survival group had higher morbidity rate for sepsis than those in the survival group. Other complications of individuals did not differ significantly. There is no significant difference in the demographic data and comorbidities of CICPs with AKI between the two groups.

Moreover, the etiology of AKI was determined for the survival and non-survival groups. We found that gastrointestinal bleeding predominately contributed to AKI in CICPs. Patients in the non-survival group were older, more likely to engage in alcohol abuse, and had higher mean parameters for serum lactate, bilirubin, CLIF-SOFA, MELD, SAPS II, and SOFA score than those in the survival group. The mean arterial pressure levels were lower and vasopressin use ratio was higher in the non-survivors than results in survivors.

In addition, calculations of SIDa and SIDe suggest that non-survivors had elevated SIG in comparison with survivors (*p* \< 0.001). A positive value for the SIG also represented increased unmeasured anions. Furthermore, there was significant difference in the acid-base and electrolyte value for the study population between the two groups ([Table 1](#t01){ref-type="table"}).

###### Characteristics of critically ill cirrhotic patients with acute kidney injury on the first day of admission, stratified by mortality

  Variable                         Survivors, *n* = 254   Non-survivors, *n* = 126   *p*
  -------------------------------- ---------------------- -------------------------- ---------
  Demographic parameters                                                             
   Age in years                    56.95 ± 10.58          57.74 ± 11.59              \<0.001
   Sex: male, *n* (%)              179 (70.47%)           91 (72.22%)                0.723
   Height in cm                    172.50 ± 8.88          170.77 ± 10.58             0.199
   Weight in kg                    83.67 ± 22.08          83.75 ± 19.53              0.973
  Survival time in days                                                              
   Death time after admission      30.00 ± 0.00           10.39 ± 8.12               \<0.001
  Etiology of cirrhosis, *n* (%)                                                     
   Alcoholic cirrhosis             104 (40.94%)           72 (57.14%)                0.030
   Non-alcoholic cirrhosis         138 (54.33%)           50 (39.68%)                0.005
   Biliary cirrhosis               8 (3.14%)              3 (2.38%)                  0.674
   Viral cirrhosis                 4 (1.57%)              1 (0.79%)                  0.529
  Etiology of AKI, *n* (%)                                                           
   Sepsis                          37 (14.57%)            50 (39.68%)                \<0.001
   Heart failure                   12 (4.72%)             6 (4.76%)                  0.987
   Gastrointestinal bleeding       88 (34.65%)            48 (38.10%)                0.509
   Respiratory failure             10 (3.93%)             5 (3.97%)                  0.988
   Hepatology renal syndrome       76 (29.92%)            45 (35.71%)                0.224
   Obstructive kidney disease      2 (0.79%)              1 (0.79%)                  0.995
  Complication                                                                       
   Sepsis                          37 (14.57%)            50 (39.68%)                \<0.001
   Gastrointestinal bleeding       88 (34.65%)            48 (38.10%)                0.509
   Hepatic coma                    22 (8.67%)             6 (4.76%)                  0.710
   Spontaneous peritonitis         1(0.39%)               2 (1.59%)                  0.216
   Respiratory failure             10 (3.93%)             5 (3.97%)                  0.988
  Comorbidity                                                                        
   Cardiac arrhythmias             36 (14.17%)            21 (16.67%)                0.522
   Chronic pulmonary disease       32 (12.60%)            22 (17.46%)                0.201
   Lymphoma                        1 (0.39%)              1 (0.79%)                  0.612
   Solid tumor                     55 (21.65%)            21 (16.67%)                0.253
   Deficiency anemias              35 (13.78%)            16 (12.70%)                0.771
   Hypertension                    76 (29.92%)            28 (22.22%)                0.113
   Diabetes Mellitus               68 (26.77%)            25 (19.84%)                0.139
  Ethnicity, *n* (%)                                                                 
   White                           192 (75.59%)           81 (64.29%)                
   African black                   17 (6.69%)             12 (9.52%)                 0.070
   Other                           45 (17.72%)            33 (26.19%)                
  Clinical parameters                                                                
   Heart rate, n.                  91.88 ± 18.93          94.25 ± 19.55              0.257
   Respiratory rate                41.57 ± 33.83          38.14 ± 32.06              0.346
   Temperature in °C               36.75 ± 0.82           36.36 ± 1.20               
   SBP in mmHg                     123.99 ± 24.30         112.49 ± 19.27             0.001
   DBP in mmHg                     65.45 ± 16.47          56.95 ± 14.90              \<0.001
   MAP in mmHg                     84.96 ± 17.22          75.47 ± 14.13              \<0.001
   Vasopressin used, *n* (%)       96 (37.80%)            84 (66.67%)                \<0.001
  Laboratory parameters                                                              
   Glucose in mg/dL                141.28 ± 76.54         123.60 ± 62.12             0.025
   White blood cell as 10^9^/L     10.58 ± 6.23           12.28 ± 7.65               0.021
   Platelet as 10^9^/L             159.56 ± 108.66        119.43 ± 72.71             \<0.001
   INR                             1.65 ± 0.57            2.45 ± 1.69                \<0.001
   Bilirubin in mg/dL              3.46 ± 5.32            8.09 ± 10.03               \<0.001
   Urine output in mL              1560.17 ± 2188.48      1332.92 ± 1868.41          0.319
   pH                              7.39 ± 0.08            7.35 ± 0.11                \<0.001
   PaCO~2~ in mmHg                 38.11 ± 9.09           35.95 ± 8.86               0.029
   HCO^3−^ in mmol/L               22.53 ± 4.96           19.54 ± 5.67               \<0.001
   BE in mmol/L                    −1.20 ± 4.62           −4.70 ± 6.25               \<0.001
   Na^+^ in mmol/L                 138.49 ± 4.94          135.54 ± 6.98              \<0.001
   Cl^−^ in mmol/L                 106.16 ± 6.08          102.60 ± 8.23              \<0.001
   K^+^ in mmol/L                  4.11 ± 0.73            4.52 ± 0.87                \<0.001
   Ca^2+^ in mmol/L                1.11 ± 0.13            1.04 ± 0.14                \<0.001
   Mg^2+^ in mmol/L                0.78 ± 0.20            0.85 ± 0.19                0.001
   Pi in mmol/L                    1.13 ± 0.48            1.62 ± 0.73                \<0.001
   Alb in g/L                      29.58 ± 6.44           25.71 ± 6.01               \<0.001
   Lactate, mmol/L                 2.80 ± 2.26            4.77 ± 3.81                \<0.001
   Creatinine in mg/dL             2.31 ± 1.78            2.12 ± 1.77                0.343
   eGFR in mL/min/1.73m^2^         48.40 ± 33.04          50.49 ± 31.72              0.556
   BUN in mmol/L                   26.52 ± 21.44          42.62 ± 29.69              \<0.001
   SBE in mmol/L                   −2.44 ± 5.54           −6.11 ± 6.93               \<0.001
   AG in mmol/L                    13.92 ± 4.76           17.92 ± 7.13               \<0.001
   AGcorr in mmol/L                19.17 ± 5.49           23.45 ± 7.48               \<0.001
   SIDa in mEq/L                   35.47 ± 4.92           34.40 ± 5.23               0.053
   SIDe in mEq/L                   31.69 ± 6.41           29.06 ± 6.10               \<0.001
   SIG in mEq/L                    3.78 ± 5.47            5.28 ± 4.77                0.011
  Clinical scores                                                                    
   CLIF-SOFA                       8.80 ± 3.21            12.01 ± 3.57               \<0.001
   MELD                            14.93 ± 8.86           25.26 ± 12.38              \<0.001
   SAPSII                          44.50 ± 13.84          53.10 ± 14.53              \<0.001
   SOFA                            7.59 ± 3.09            10.35 ± 3.47               \<0.001

Abbreviations: CLIF-SOFA, chronic liver failure-sequential organ failure assessment score; DBP, diastolic blood pressure; INR, international normalized ratio; MELD, model for end-stage liver disease; SBP, systolic blood pressure; MAP, mean arterial pressure; SAPSII, simplified acute physiology score; BUN, blood urea nitrogen; PaO~2~, partial pressure of oxygen; PaCO~2~, partial pressure of carbon dioxide; FIO~2~, fraction of inspiration O~2~; BE, base excess; SBE, standard base excess; Na^+^, sodium; Cl^−^, chloride; Alb, albumin; Ca^2+^, ionized calcium; Pi, inorganic phosphate; Mg^2+^, magnesium; AG, anion gap; SID, strong ion difference; SIDa, the apparent SID; SIDe, the effective SID; UMA, unmeasured anions; AGcorr, anion gap corrected for albumin; eGFR, evaluated glomerular filter rate; AKI, acute kidney injury.

Disequilibrium of acid-base disorders in CICPs with AKI {#s3-2}
-------------------------------------------------------

Net metabolic acidosis, compensated by respiratory alkalosis, was attributed to acidosis caused by unmeasured anions, hyperchloremic, lactic acidosis, and mild dilutional acidosis. In contrast, hypoalbuminemia was the only alkalinizing element that contributed to alkalosis in both groups. As illustrated in [Fig. 1](#f01){ref-type="fig"}, non-survivors had more severe metabolic acid-base disorders than the survival group. The mean levels of BE~Lac~, BE~UMA~, and BE~Na~ were remarkably decreased in the survival group.

![Disequilibrium of metabolic acid-base disorders in CICPs with AKI between non-survivors and survivors.\
Acidosis owing to unmeasured anions and lactate, hyperchloremic acidosis and dilutional acidosis outweigh hypoalbuminemic alkalosis, resulting in net metabolic acidosis. Metabolic acid-base analysis was performed applying Gilfix methodology, based on the concept that net base excess (BE) is determined by effect of free water excess (BE~Na~), changes in concentrations of chloride (BE~Cl~), albumin (BE~Alb~), lactate (BE~Lac~) and the accumulation of unmeasured anions (BE~UMA~): BE = BE~Na~ + BE~Cl~ + BE~Alb~ + BE~Lac~ + BE~UMA~.](JCTH-7-112-g001){#f01}

Acid-base state and hospital mortality in CICPs with AKI {#s3-3}
--------------------------------------------------------

Mean parameters of pH, HCO^3−^, and BE were reduced, whereas that of AG was elevated in non-survivors because of elevated lactate and unmeasured anions. The composition frequencies of acidemia, net metabolic acidosis, lactic acidosis, acidosis based on unmeasured anions, and dilutional acidosis were significantly different between the two groups ([Table 2](#t02){ref-type="table"}). In a subgroup analysis, scatter plots showed observed hospital 30-day mortality rate for patients to be associated with the value of the associated acid-base marker in admission to ICU. We found a positive correlation between hospital mortality and acid-base parameters at different intervals rather than a linear trend; this suggests that fluctuation of acidotic markers may have a contributing role in hospital mortality and that maintaining these markers in the normal range could potentially reduce mortality ([Fig. 2](#f02){ref-type="fig"}).

###### Frequencies of acid-base disorders with critically ill cirrhosis with AKI, stratified by mortality

                                        Survivors, *n* = 254   Non-survivors, *n* = 126   *p*
  ------------------------------------- ---------------------- -------------------------- ---------
  Acidemia                              70 (27.5%)             59 (46.82%)                \<0.001
  Alkalemia                             58 (22.8%)             23 (18.3%)                 0.674
  Net metabolic acidosis                46 (18.11%)            52 (41.27%)                \<0.001
  Dilutional acidosis                   3 (1.18%)              5 (3.97%)                  0.075
  Net metabolic alkalosis               17 (6.69%)             7 (5.56%)                  0.733
  Hyperchloremic acidosis               115 (45.28%)           37 (29.37%)                0.254
  Hypochloremic alkalosis               30 (11.81%)            42 (33.33%)                \<0.001
  Acidosis owing to unmeasured anions   64 (25.20%)            77 (61.11%)                \<0.001
  Hypoalbuminemic alkalosis             114 (44.88%)           77 (61.11%)                0.003
  Lactic acidosis                       124 (48.82%)           88 (69.84%)                \<0.001

![The 30-day hospital mortality of the associated acid-base marker in different intervals.](JCTH-7-112-g002){#f02}

Moreover, hospital mortality rate was further assessed by comparing the hazard ratio in univariate and multivariate analyses. In these analyses, the presence of acidemia, acidosis owing to unmeasured anions, as well as lactic acidosis were each associated with increased ICU 30-day mortality rate with hazard ratio of 2.11 (95% CI: 1.43--3.12), 3.38 (95% CI: 2.36--4.84), and 2.16 (95% CI: 1.47--3.35), respectively ([Table 3](#t03){ref-type="table"}). After adjusting traditional confounders in model 3, the relationship between acidosis owing to unmeasured anions with mortality rate was still significantly positive. Furthermore, the diagnostic accuracy of arterial lactate and BE~UMA~ concentrations in predicting mortality rate is sound, with a relatively linear correlation to risk of observed mortality.

###### Association of acid-base state with ICU 30-day mortality in critically ill cirrhotic patients with AKI

                                        Model 1             *p*       Model 2             *p*       Model 3             *p*
  ------------------------------------- ------------------- --------- ------------------- --------- ------------------- -------
  Acidemia                              2.11 (1.43--3.12)   \<0.001   1.67 (0.99--2.78)   0.051     0.98 (0.50--1.91)   0.948
  Alkalemia                             1.11 (0.67--1.84)   0.684     0.73 (0.34--1.57)   0.422     1.64 (0.47--5.55)   0.424
  Net metabolic acidosis                2.65 (1.84--3.81)   \<0.001   2.10 (1.26--3.49)   0.004     0.91 (0.48--1.75)   0.914
  Dilutional acidosis                   2.18 (0.89--5.34)   0.088     1.20 (0.27--5.27)   0.811     1.38 (0.25--7.52)   0.711
  Hyperchloremic acidosis               0.78 (0.51--1.20)   0.263     0.66 (0.37--1.17)   0.154     0.68 (0.33--1.40)   0.680
  Hypochloremic alkalosis               2.45 (1.61--3.71)   \<0.001   1.57 (0.86--2.87)   0.141     1.19 (0.53--2.68)   0.670
  Acidosis owing to unmeasured anions   3.38 (2.36--4.84)   \<0.001   3.20 (1.96--5.24)   \<0.001   2.29 (1.22--4.30)   0.010
  Hypoalbuminemic alkalosis             1.75 (1.22--2.50)   0.002     1.81 (1.11--2.94)   0.017     0.80 (0.35--1.83)   0.598
  Lactic acidosis                       2.16 (1.47--3.15)   \<0.001   1.58 (0.97--2.56)   0.065     0.85 (0.37--1.93)   0.691

Model 1 is univariate analysis. Model 2 includes Model 1 plus age, sex, height, weight and complication (hypertension, diabetes mellitus, cardiac arrhythmias, chronic pulmonary disease, lymphoma, solid tumor, and iron deficiency anemias). Model 3 includes Model 2 plus comorbidities (sepsis, gastrointestinal bleeding, respiratory failure, hepatic coma, and spontaneous peritonitis), cause of liver cirrhosis (alcoholic cirrhosis, non-alcoholic cirrhosis, biliary cirrhosis, and viral cirrhosis), laboratory parameters (eGFR, white blood cell, platelet, albumin, lactate, and hematocrit), and chronic liver failure-sequential organ failure assessment score.

The ability to predict hospital mortality by CLIF-SOFA (with lactate: AUROC of 0.76, 95% CI: 0.71--0.81; without lactate: AUROC of 0.74, 95% CI: 0.70--0.79) showed similar strength as CLIF-SOFA + BE~UMA~ (AUROC of 0.76, 95% CI 0.71--0.80). Overall, arterial lactate concentration in combination with the CLIF-SOFA and BE~UMA~ had the strongest ability to predict 30-day mortality (AUROC of 0.79, 95% CI: 0.74--0.83) ([Table 4](#t04){ref-type="table"} and [Fig. 3](#f03){ref-type="fig"}).

###### Performance of different prognostic models in predicting 30-day mortality using the optimal cut-off point

  Prognostic model            AUROC   95% CI       *p* (vs. CLIF-SOFA)   Cut-off   Sensitivity, %   Specificity, %   PLR    NLR    PPV     NPV
  --------------------------- ------- ------------ --------------------- --------- ---------------- ---------------- ------ ------ ------- -------
  CLIF-SOFA                   0.74    0.70--0.79                         12.00     49.21            87.01            3.79   0.58   65.30   77.50
  LAC                         0.68    0.63--0.73   0.008                 2.50      62.61            65.37            1.81   0.57   47.40   77.80
  BE~UMA~                     0.69    0.64--0.74   0.171                 −4.63     62.40            74.41            2.44   0.51   54.50   80.10
  CLIF-SOFA + LAC             0.76    0.71--0.81   0.049                 3.79      56.80            83.46            3.44   0.52   62.80   79.70
  CLIF-SOFA + BE~UMA~         0.76    0.71--0.80   0.731                 0.78      68.80            77.95            3.12   0.40   60.60   83.50
  CLIF-SOFA + LAC + BE~UMA~   0.79    0.74--0.83   \<0.001               2.79      56.00            87.80            4.59   0.50   69.30   80.20

Abbreviations: CLIF-SOFA, chronic liver failure-sequential organ failure assessment score; LAC, lactate; NLR, negative likelihood ratio; NPV, negative predictive value; PLR, positive likelihood ratio; PPV, positive predictive value.

![Area under the receiver operating characteristic curve analysis of different models in predicting 30-day mortality.\
Chronic liver failure-sequential organ failure assessment (CLIF-SOFA) showed improvement in discriminative ability by combining lactate and BE~UMA~, as compared with CLIF-SOFA alone.](JCTH-7-112-g003){#f03}

Discussion {#s4}
==========

Mounting evidence suggests that applying Stewart equations and the Gilfix methodology to acid-base can easily and accurately identify crucial metabolic acid-base abnormalities.[@b20] This method has high application in critically ill patients, but few reports on its usefulness in CICPs with AKI exist in the literature. In this study, we performed a retrospective analysis of 380 CICPs with AKI in the ICU and demonstrated that these types of patients had imbalance of metabolic acid-base.

Several significant findings emerged from our investigation. Firstly, our study showed metabolic acid-base abnormalities in non-survival and survival groups. Mean parameters of pH, HCO^3−^, and BE were reduced, while that of AG was elevated in non-survivors because of increased lactate and unmeasured anions. Secondly, the SIG plays an important effect on Stewart's acid-base physiology. It is shown that an increase in SIG of non-survivors partly counteracted the decrease in partial pressure of carbon dioxide and other weak acids. Although SIG was higher in non-survivors than in survivors, it was not a pivotal predictor of outcome in our study. Thirdly, the development of acidemia, mainly attributed to increased unmeasured anions and lactic acidosis, had a positive relationship, independently, with increased ICU 30-day mortality.

Our finding confirmed that CICPs with AKI is a state of metabolic acidosis. We found decreases in pH, HCO^3−^, BE, BE~UMA~, and chloride levels, as well as increases in lactate and SIG in the non-survival group. In addition, the components determining BE and the effect of changes in albumin, sodium, lactate and chloride levels were analyzed and quantified. We demonstrated that these parameters were positively correlated with hospital mortality and that the frequencies of net metabolic acidosis, acidosis owing to unmeasured anions, and lactic acidosis were higher in non-survivors. Thus, understanding lactic acidosis and components of unmeasured anions is crucial in these patients.

In the normal physiologic state, a total amount of 1500 mmol of lactate is produced in the human body daily from the reduction of pyruvate by enzyme lactate dehydrogenase, with lactate levels maintained at \<2 mmol/L.[@b21] However, in pathological conditions exposed to tissue hypoxia and anaerobic state, pyruvate is promptly accumulated and its metabolism is almost entirely shifted to lactate production.[@b22]--[@b24] In physiological conditions, the generation and consumption of lactate are strictly balanced. The liver and kidney are well known for lactate dehydrogenase dysfunction in the setting of CICPs with AKI.[@b22],[@b25] Therefore, hyperlactatemia is common in CICPs with AKI and elevated serum lactate can gradually increase hospital mortality. The elevation of lactate can result from both increased lactate production and decreased hepatic lactate elimination. Moreover, patients who suffer from sepsis might also partly interpret the production of lactate. In our previous study, we revealed that initial lactate concentration strongly and independently predicted short- and long-term hospital outcome in CICPs with AKI.[@b16]

In our evaluation of components contributing to BE, we discovered that CICPs with AKI had significant hypoalbuminemic alkalosis in combination with acidosis owing to unmeasured anions, even after adjusting for confounders. In the non-survival group, acidosis secondary to unmeasured anions was found to be significant, and hospital mortality was notably higher as BE~UMA~ value became lower than -4.14 mmol/L. Some unmeasured anions might be the result of retained organic anions, attributed to AKI, during BE~UMA~ evaluation.[@b26] Furthermore, among the examined acid-base parameters, BE~UMA~ had the best discrimination and did not differ significantly with CLIF-SOFA. Thus, BE~UMA~ in combination with lactate levels and CLIF-SOFA score have markedly reinforced our ability to predict mortality in CICPs with AKI. As a secondary outcome, we found that decreased serum albumin was associated with abnormal liver function and expenditure, which might possibly indicate a need for nutrition assessment. All together, these observations emphasize that imbalance of the acid-base state reflects hospital mortality of CICPs with AKI.

A few potential limitations exist in our study. Firstly, we recognize that the results from a single center may not fully reflect all the subjects' conditions. Secondly, sequential measurement of acid-base disorders may provide a better insight into the mechanisms of metabolic acidosis. Thirdly, specific treatments of acid-base disorders benefiting CICPs with AKI are yet to be defined.

In conclusion, this study confirmed that CICPs with AKI exhibit a complex metabolic acidosis during ICU admission. There was highly significant difference between the survivors and the non-survivors for lactate and BE~UMA~ of acid-base state in the CICPs with AKI, which can be used to determine mortality outcome. This physiochemical methodology to assess acid-base disorders showed great value with important prognostic implication, thus highlighting the need to control metabolic acidosis.
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AKI

:   acute kidney injury

AG

:   anion gap

AUROC

:   area under the receiver operating characteristic curve

BE

:   base excess

CI

:   confidence interval

CICPs

:   critically ill cirrhotic patients

CLIF-SOFA

:   chronic liver failure-sequential organ failure assessment

HCO^3−^

:   bicarbonate

ICU

:   intensive care unit

KDIGO

:   kidney disease improving global outcomes

MIMIC-III v3.0

:   Multiparameter Intelligent Monitoring in Intensive Care Database III version 3.0

SAPS

:   simplified acute physiology score

SCr

:   serum creatinine

SIDa

:   strong ion difference-apparent

SIDe

:   strong ion difference-effective

SIG

:   strong ion gap
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